Summary:
A 67-year-old man with AML, who had a 21-year history of psoriasis without remission, received a reduced-intensity transplantation from an HLA-identical sibling. The preparative regimen consisted of busulfan and fludarabine. Graft-versus-host-disease (GVHD) prophylaxis was cyclosporine and methotrexate. Psoriasis was completely resolved on day 18. The subsequent clinical course was uneventful until day 42, when psoriasis recurred at the same sites as before RIST. Peripheral blood examined on day 63 showed mixed chimerism with 54% recipient type. Cyclosporine was rapidly tapered off over the next 2 weeks. On day 90, 100% donor-type chimerism was confirmed. Subsequently, psoriasis improved simultaneously with the occurrence of mucositis and rash as a manifestation of GVHD. Scattered erythematous patches of psoriasis disappeared again by day 105. We initiated 0.5 mg/kg prednisolone on day 119, and resumed cyclosporine on day 133. At 7 months after RIST, he still suffers from chronic GVHD, but his psoriasis remains in remission for the first time in 21 years. The anti-psoriasis effect of the conditioning is mild and transient, while the graft-versus-autoimmunity effect, related to the induction of complete donor-type chimerism and GVHD, is more profound and persisting. A graft-versus-autoimmunity effect lies in the delicate balance between alloimmunity and immunosuppressant used for GVHD prophylaxis/treatment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Binks M, Passweg JR, Furst D et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 2001; 60: 577–584.
Burt RK, Slavin S, Burns WH, Marmont AM . Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure? Blood 2002; 99: 768–784.
Burt RK, Slavin S, Burns WH, Marmont AM . Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure? Int J Hematol 2002; 76 (Suppl 1): 226–247.
Snowden JA, Biggs JC, Milliken ST et al. A phase I/II dose escalation study of intensified cyclophosphamide and autologous blood stem cell rescue in severe, active rheumatoid arthritis. Arthr Rheum 1999; 42: 2286–2292.
Marmont AM . Immunoablation followed or not by hematopoietic stem cells as an intense therapy for severe autoimmune diseases (SADS). New perspectives, new problems. Haematologica 2000; 85 (Suppl): 71–80.
Marmont AM . Immunoablation followed or not by hematopoietic stem cells as an intense therapy for severe autoimmune diseases. New perspectives, new problems. Haematologica 2001; 86: 337–345.
Slavin S, Nagler A, Varadi G, Or R . Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis. Exp Hematol 2000; 28: 853–857.
Saito T, Kanda Y, Kami M et al. Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma. Clin Cancer Res 2002; 8: 1014–1020.
Fredriksson T, Pettersson U . Severe psoriasis–oral therapy with a new retinoid. Dermatologica 1978; 157: 238–244.
Chakrabarti S, Handa SK, Bryon RJ et al. Will mixed chimerism cure autoimmune diseases after a nonmyeloablative stem cell transplant? Transplantation 2001; 72: 340–342.
Adkins DR, Abidi MH, Brown RA et al. Resolution of psoriasis after allogeneic bone marrow transplantation for chronic myelogenous leukemia: late complications of therapy. Bone Marrow Transplant 2000; 26: 1239–1241.
Spitzer TR, Sykes M . Treatment of renal-cell cancer by transplantation of allogeneic stem cells. N Engl J Med 2001; 344: 137–138.
Khouri IF, Saliba RM, Giralt SA et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001; 98: 3595–3599.
Giralt S, Aleman A, Anagnostopoulos A et al. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant 2002; 30: 367–373.
Michallet M, Bilger K, Garban F et al. Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pre transplantation and post transplantation factors on outcome. J Clin Oncol 2001; 19: 3340–3349.
Davidson A, Diamond B . Autoimmune diseases. N Engl J Med 2001; 345: 340–350.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kojima, R., Kami, M., Kim, SW. et al. Induction of graft-versus-autoimmune (GVA) disease effect against refractory psoriasis by complete donor-type chimerism and graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 32, 439–442 (2003). https://doi.org/10.1038/sj.bmt.1704146
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1704146
Keywords
This article is cited by
-
Psoriasis in the transplant population
Archives of Dermatological Research (2022)
-
Allogene hämatopoetische Stammzelltransplantation
Zeitschrift für Rheumatologie (2016)
-
Hematopoietic stem cell transplantation for pediatric autoimmune disease: where we stand and where we need to go
Bone Marrow Transplantation (2009)
-
Allogeneic haematopoietic stem cell transplantation for severe autoimmune diseases: great expectations but controversial evidence
Bone Marrow Transplantation (2006)